The study sought to evaluate for the first time the 5-year outcomes after treating an all-comers population with newer-generation cobalt chromium-based Resolute Integrity zotarolimus-eluting stents (ZES) (Medtronic, Santa Rosa, California) versus platinum chromium-based PROMUS Element everolimus eluting stents (EES) (Boston Scientific, Natick, Massachusetts).
In patients on oral anticoagulation, triple therapy was generally prescribed for 1 to 3 months, followed 
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RESULTS
Out of all 1,811 patients, 5-year clinical follow-up data were available in 1,798 patients (99.3% follow-up:
3 patients were lost to follow-up and 10 withdrew consent) ( Figure 1 ). As previously reported, there were no differences in baseline clinical and lesion characteristics between patients randomized to treatment with ZES versus EES ( target vessel-related MI (3.1% vs. 2.6%; log-rank p ¼ 0.47); and target vessel revascularization (7.6% vs.
8.6%; log-rank p ¼ 0.46), respectively ( Figure 2 ). In addition, the rates of the composite endpoints TLF (12.0% vs. 12.5%; log-rank p ¼ 0.86), MACE (17.0% vs.
17.2%; log-rank p ¼ 0.97), and the patient-oriented composite endpoint (22.8% vs. 23.3%; log-rank p ¼ 0.86) were similar for both groups ( Table 3) .
As shown in Value are n (%) or mean AE SD. Details of lesion characteristics and interventional procedure have previously been reported. *Including chronic total occlusion, but not grafts or in-stent restenosis.
ACC/AHA ¼ American College of Cardiology/American Heart Association; other abbreviations as in Table 1 . Values are n (%).
CI ¼ confidence interval; other abbreviations as in Table 1 .
FIGURE 2 Kaplan-Meier Curves for Target Vessel Failure and the Individual Components Thereof
Kaplan-Meier curves for (A) target vessel failure, (B) cardiac death, (C) target vessel-related myocardial infarction, and (D) target vessel revascularization for patients treated with the Resolute Integrity ZES (yellow) versus PROMUS Element EES (gray). Abbreviations as in Figure 1 . 
